Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spero Therapeutics reports progress in drug candidates and financial stability

Spero Therapeutics showcased progress in key drug candidates and financial stability.
Efficient management of expenses and strong cash position support future operations.
Challenges include successful Phase III trials and proof of concept for key treatments.
Opportunities lie in market potential for drug candidates and positive financial outlook.

Spero Therapeutics advances clinical programs and strengthens financial position

Spero Therapeutics demonstrated strong clinical and financial performance in Q1 2023, with a robust pipeline and efficient cost management.
While facing timeline challenges and the need for regulatory milestones, the company's strengths in infectious disease treatments and strategic partnerships present growth opportunities.
By addressing challenges, leveraging strengths, and capitalizing on opportunities, Spero is poised for continued success and potential market leadership in the pharmaceutical sector.

Spero Therapeutics reports Q2 progress with strategic leadership changes

Spero Therapeutics reported Q2 revenues of $2.7 million with a net loss of $11.9 million, holding $77.7 million in cash.
Progress in late-stage clinical programs and management changes signal strategic advancements and leadership continuity.
Challenges include managing R&D investments, competitive market dynamics, and clear execution of growth strategies.
Opportunities lie in revenue growth from milestones, pipeline expansion, differentiation strategies, and strategic partnerships.

Spero Therapeutics reports strong Q3 performance amidst strategic shifts

Spero Therapeutics showcased solid revenue generation and cash reserves in Q3 2023, underpinned by strategic partnerships and pipeline advancements.
While facing challenges such as increased expenses and impairment costs, the company's leadership changes and innovative programs position it for long-term success.
Opportunities lie in upcoming clinical data releases, expansion of product pipelines, and substantial revenue potential from key partnerships, signaling a promising outlook for Spero.

Spero Therapeutics excels in antibiotic development with strong financial backing

Spero Therapeutics demonstrated strong performance in advancing key programs and securing financial support, positioning the company for future growth.
While facing challenges in enrollment and funding, the opportunities in addressing critical infections present a promising outlook for Spero Therapeutics.

Spero Therapeutics reports Q2 revenue growth amidst leadership transition

Spero Therapeutics showcased solid revenue but faced rising R&D costs and leadership changes.
The company's financial stability is supported by cash reserves and expected milestone payments.
Opportunities lie in pipeline advancements, upcoming data releases, and strategic investor communication.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 43rd Annual Healthcare Conference, which is taking place March 6-8, 2023, at the Boston Marriott Copley Place in Boston, MA, and Oppenheimer's 33rd Annual Healthcare Conference, which is taking place virtually, March 13-15, 2023. Details are as follows:

Spero Therapeutics to Present at Upcoming Investor Conferences

Spero Therapeutics, Inc. (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround

Spero Therapeutics, Inc. (SPRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer Kamal Hamed - Chief Medical Officer Sat Shukla - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Louise Chen - Cantor Ritu Baral - Cowen Operator Good afternoon and welcome to the Spero Therapeutics' Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of common stock, with potential for future milestone payments and tiered royalties

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future milestone payments and tiered royalties Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future milestone payments and tiered royalties

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Spero Therapeutics, Inc. (SPRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced data presentations for 7 abstracts accepted at the Infectious Disease Society of America (IDSA) IDWeek™ 2022, taking place from October 19 – 23, 2022 in Washington, DC.

Spero Therapeutics to Present Data at IDWeek 2022

Akero Therapeutics Inc

Applied DNA Sciences

Avenue Therapeutics

HeartBeam

Immuneering Corp

Mind Medicine MindMed

PhaseBio Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings Inc

Virios Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

Event is taking place on Thursday, October 6 th at 11:30 a.m. ET

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related milestone payment, equivalent to $3.2 per share, associated with Phase 3 clinical trial provides sufficient upside from today's share price.

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Adverum Biotechnologies

 Clene Nanomedicine

Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?

Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October

Pulse Biosciences

Alaunos Therapeutics

Hot penny stocks to add to your watch list this week. Is it time to buy?

Hot Penny Stocks To Watch As The Stock Market Crash Continues

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

American Virtual Cloud Technologies

Check these Reddit penny stocks out for your watchlist right now The post Reddit Penny Stocks to Watch as September Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Reddit Penny Stocks to Watch as September Ends

GlaxoSmithKline

Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.

Spero's stock jumps 188% after GSK licenses experimental antibiotic

Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers the rights to tebipenem HBr, which is an antibiotic asset in late-stage development by Spero Therapeutics.

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

IMARA

Mullen Automotive

Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?

Looking for Popular Penny Stocks to Buy? 3 to Watch Now

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

News for Spero Therapeutics Stock (SPRO)